Last edition
News about Global Pharma
Arthrex Launches Synergy Power for Versatile Orthopedic Procedures
Arthrex announces the launch of Synergy Power™, a versatile and reliable battery-powered system designed for a wide variety of orthopedic applications.
Global Pharma | 04/06/2025 | By Manvi | 142
Tixel i Shows Strong, Lasting Results for Dry Eye Treatment in JOJ Ophthalmology Study
This FDA-cleared, non-invasive device uses patented Thermo-Mechanical Action® (TMA®) to deliver durable improvements in key indicators, including patient satisfaction and clinical results.
Global Pharma | 04/06/2025 | By Manvi | 146
Gland Pharma Secures Approval for Angiotensin II Acetate Injection
Gland Pharma has received USFDA approval for its Angiotensin II Acetate Injection, securing 180-day exclusivity as the First-to-File generic of GIAPREZA for treating distributive shock.
Global Pharma | 04/06/2025 | By Manvi | 203
UK's MHRA Grants Approval to Aumolertinib for Treatment of Non-Small Cell Lung Cancer
The UK’s MHRA has approved aumolertinib (Aumseqa) for adults with advanced non-small cell lung cancer carrying EGFR mutations, offering a new targeted treatment option for metastatic cases.
Global Pharma | 04/06/2025 | By Manvi | 453
Perma and UE Systems Launch UltraTrak VARIO for Smart Industrial Lubrication
perma has joined forces with UE Systems to redefine industrial lubrication. Central to this strategic partnership is the launch of the UltraTrak VARIO, a new solution within the OnTrak Wireless ecosystem.
Global Pharma | 03/06/2025 | By Manvi | 399
Johnson & Johnson MedTech Launches KINCISE 2 Surgical Automation System
Johnson & Johnson MedTech announced the launch of the KINCISE 2™ Surgical Automated System, a next-generation automated power tool engineered to improve surgical efficiency, provide control and aims to reduce physical burden on surgeons compared to manual impaction across both primary and revision hip and revision knee replacement procedures.
Global Pharma | 03/06/2025 | By Manvi | 274
Sun Pharma has announced that its Phase 2 trials for SCD-044 in psoriasis and atopic dermatitis did not meet primary efficacy endpoints of 75 percent improvement in PASI (Psoriasis Area and Severity Index) score (PASI75) at Week 16, prompting discontinuation of further development.
Global Pharma | 03/06/2025 | By Manvi | 235
Biocon Secures Approval for Diabetes Drug Liraglutide in India
Biocon Ltd. has received approval in India for its Liraglutide drug substance and drug product, marking a key milestone in expanding access to GLP-1 therapy for Type 2 diabetes.
Global Pharma | 03/06/2025 | By Manvi | 345
ASP Isotopes and Isotopia Ink Deal to Secure Gd-160 Supply for Cancer Therapy
This partnership addresses longstanding supply challenges for Gd-160, enabling Isotopia to advance Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies.
Global Pharma | 02/06/2025 | By Manvi | 320
Zydus Secures Tentative Approval from USFDA for Rifaximin Tablets, 550 mg
Zydus Lifesciences has received tentative USFDA approval for Rifaximin Tablets, 550 mg, used to treat IBS-D in adults.
Global Pharma | 02/06/2025 | By Manvi | 260
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy